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Abstract
Background: In patients hospitalized for myocardial infarction, there are limited data examining the long-term 
prognostic effect of diabetes.
The aim of this study was to systematically evaluate the development of diabetes as an independent long-term
prognostic factor after myocardial infarction.
Methods: Prospective follow-up of 6676 consecutive MI patients screened for entry in the Trandolapril Cardiac 
Evaluation (TRACE) study. The patients were analysed by Kaplan-Meier survival analysis, landmark analysis and Cox 
proportional hazard models and outcome measure was all-cause mortality.
Results: The mortality in patients with diabetes was 82,7% at 10 years of follow-up and 91,1% at 15 years of follow-up, 
while patients without diabetes had a mortality of 60,2% at 10 years of follow-up and 72,9% at 15 years of follow-up (p 
< 0.0001). Landmark analysis continued to show prognostic significance of diabetes throughout the duration of follow-
up. Multivariable Cox proportional-hazards model showed that the hazard ratio for death in patients with diabetes 
overall was 1.47 (95% confidence intervals (CI) 1.35-1.61) and varied between 1.19 (CI 1.04-1.37) and 2.13 (CI 1.33-3.42) 
in the 2-year periods of follow-up.
Conclusions: Diabetes is an important independent long-term prognostic factor after MI and continues to predict 
mortality even 17 years after index MI.
This underscores the importance of aggressive diagnostic and therapeutic approach in diabetes patients with MI.
Background
Disturbances in glucose metabolism are frequent in
patients with ischemic heart disease, and abnormal glu-
cose tolerance in MI patients is almost twice as common
as hypertension and dyslipidemia [1]. The Glucose
Metabolism in Patients with Acute Myocardial Infarction
(GAMI) study documented a high prevalence of diabetes
and abnormal glucose tolerance in patients MI and no
known diabetes [2]. Diabetes increases long-term mortal-
ity following MI [3,4], and patients requiring glucose-
lowering therapy exhibit a cardiovascular risk of the same
magnitude as patients without diabetes with a prior myo-
cardial infarction, regardless of gender and diabetes type
[5]. As a result, patients with diabetes should receive pro-
phylactic treatment for cardiovascular disease, but many
remain undiagnosed thus missing this treatment effect
[6]. Moreover, the most recent guidelines recommend
that patients with myocardial infarction are screened for
diabetes, including an oral glucose tolerance test when
necessary, but this recommendation is new and not
widely followed [7]. As a result, it is important to know
whether diabetes as an important risk factor does not
deteriorate over time even when cardiovascular disease is
established, underlining the importance of an aggressive
approach towards diagnosing diabetes in MI patients.
However, data examining the long-term prognostic effect
of diabetes after MI are scarce, and there is lack of infor-
mation in the variation of the prognostic effect of diabe-
tes over time in MI patients.
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We undertook a retrospective study of 6676 consecu-
tive patients admitted with myocardial infarction and
screened for entry in the TRACE study. The purpose was
to systematically evaluate the long-term development of
t h e  p r o g n o s t i c  i m p o r t a n c e  o f  d i a b e t e s  a s  a  r i s k  f a c t o r
evaluated at the time of the index infarction.
Methods
Subject and study design
The Trandolapril Cardiac Evaluation (TRACE) registry
has been described in detail previously [8,9]. In brief, the
TRACE registry consist of the 6676 MI patients screened
for entry in the TRACE study, which was a double-blind,
randomized, parallel group, placebo-controlled study of
trandolapril versus placebo in patients with left ventricu-
lar dysfunction after MI. The study was conducted in 27
centres in Denmark, and participating centres were
required to screen consecutive patients admitted with MI
2-6 days after the infarction and provide data on each
patient for the registry. The diagnostic criteria of myocar-
dial infarction were chest pain and/or electrocardio-
graphic changes suggestive of ischemia or infarction,
accompanied with elevated cardiac enzymes. Left ven-
tricular systolic function was evaluated in a core lab as
wall motion index using a 9-segment model and a reverse
scoring system. Wall motion index multiplied by 30
approximates left ventricular ejection fraction. The tech-
nique has previously been described in detail and vali-
dated [10]. Of the screened patients, 1749 (26.2%) were
randomised to trandolapril or placebo in the TRACE
study.
The TRACE study was approved by all regional ethical
committees in Denmark and complies with the 1975 Dec-
laration of Helsinki. Informed consent was obtained from
each patient. The study was registered with the National
Board of Health and the Danish Data Protection Agency.
All participating patients provided informed consent.
Follow-up data
All Danish citizens are given a unique and permanent
person registry number. All deaths in Denmark are regis-
tered in the central person registry within 2 weeks and all
deaths are confirmed by a death certificate. Follow-up
mortality data were provided by a computerized analysis
from the Danish Central Personal Registry by 16.06.2008.
Statistical analysis
The base-line characteristics of the study population
were compared with a t-test for continuous variables and
a chi-square test for discrete variables. Mortality was ana-
lyzed with Kaplan-Meier curves. We used Landmark
analyses to illustrate the prognostic significance of diabe-
tes in 2-year intervals. Relative risk for death and the
associated 95 percent confidence intervals were calcu-
lated as hazard ratios derived from a Cox proportional-
hazards regression model. We used stepwise models
including increasing number of variables. The models
fulfilled the Cox regression model assumptions (linearity
of continuous variables, proportional hazards assumption
and lack of interaction) unless otherwise specified. Statis-
tical analyses were performed with the Statistical Analy-
sis System, ver. 9.1 (SAS Institute, Cary, NC, USA).
Results
Baseline characteristics
A total of 7001 MI's in 6676 patients were reported from
May 1990 to August 1992. By the end of follow-up, the
mortality was 5231 patients (78.4%). 38 patients (0.56%)
were lost to follow-up or emigrated and were censured on
the last day they were known to be alive.
Baseline characteristics of the 6668 patients included in
our study are listed in table 1. There were missing data on
diabetes status on 8 patients. Patients with diabetes were
older, had more co-morbidity and risk factors, received
more often diuretics but less often thrombolytic therapy,
had poorer left ventricular function and were in higher
New York Heart Association (NYHA) and Killip class. All
the mentioned differences were statistically significant.
At the start of the study, there were 156 (2.34%) patients
with diabetes treated with diet, 372 (5.58%) with diabetes
treated with oral medication, and 140 (2.10%) with
patients with diabetes treated with insulin. There were
missing data on treatment in 5 patients.
Analysis of all-cause mortality
As expected, patients with diabetes had a significantly
higher mortality than patients without diabetes (figure 1,
unadjusted analysis). The mortality in patients with dia-
betes was 82,7% and 91,1% at 10 and 15 years of follow-up
while patients without diabetes had a mortality of 60,2%
and 72,9% at 10 and 15 years of follow-up (p value <
0.0001 for difference between patients with and without
diabetes). To clarify the importance of diabetes as a prog-
nostic factor we performed landmark analysis illustrating
survival in diabetics and non diabetics adjusted for age,
sex and wall motion index in 2 year intervals after the
infarction (Figure 2). The Landmark analysis demon-
strated that diabetes continued to have a significant prog-
nostic effect throughout the duration of follow-up.
We constructed Cox proportional-hazards models of
total mortality with stepwise addition of covariates (Table
2). Age was a significant prognostic factor throughout the
length of follow-up in all models. The hazard ratio (HR)
varied between 1.45 (95% Confidence Interval [CI] 1.37-
1.54) and 2.14 (CI 1.68-2.71) per 10 years increase in
patient age in the model incorporating all covariates. For
the entire follow-up period, diabetes was a significant
prognostic factor, hazard ratio 1.47 (CI 1.35-1.61)Kümler et al. Cardiovascular Diabetology 2010, 9:22
http://www.cardiab.com/content/9/1/22
Page 3 of 8
adjusted for all covariates. Greater significance of diabe-
tes reflected in a higher hazard ratio was observed in the
end of follow-up, however this did not reach statistical
significance in the last period of follow-up, most likely as
a result of lack of statistical power since only few patients
with diabetes were still alive at this time. Relative risks in
the model without covariates (model 1) and with all cova-
riates (model 3) in each of the 2-year periods of follow-up
are illustrated in figure 3. HR for diabetes varied between
1.19 (CI 1.04-1.37) and 2.13 (CI 1.33-3.42) in the fully
adjusted models and reached significance in most of the
2-year intervals. The hazard ratio associated with male
gender was between 0.99 (CI 0.89-1.10) and 1.64 (CI
1.27-2.12) and did not reach statistical significance in
most of the 2-year interval. Overall, male gender was
associated with a small, but significant increase in risk of
death, hazard ratio 1.11 (CI 1.04-1.18).
Discussion
This study describes the long-term prognostic signifi-
cance of diabetes in a large population of consecutive
patients with MI. With a follow-up of 17 years, we found
that diabetes continued to represent a strong indepen-
dent prognostic factor for all-cause mortality. This is a
Table 1: Patient characteristics according to diabetes classification.
Diabetes (n = 719) No diabetes (n = 5949) P Value
Age (SD) 69.5 67.1 <0.0001
Gender. % 41.3 31.5 <0.0001
Women 58.7 68.5
Men
Body mass index (SD) 26.7 25.6 <0.0001
Creatinine (mean). μmol/l 117 107 <0.0001
Hypertension. % 36.3 21.0 <0.0001
Angina pectoris % 48.1 35.5 <0.0001
Previous MI. % 32.3 22.3 <0.0001
Heart failure*. % 69.0 51.8 <0.0001
Current smoking. % 36.1 53.4 <0.0001
Thrombolysis. % 27.0 42.5 <0.0001
Previous stroke. % 13.2 7.6 <0.0001
Diuretic treatment. % 64.2 42.3 <0.0001
NYHA. %
Class I 47.0 58.4 <0.0001
Class II 34.8 28.3
Class III 6.9 3.9
Class IV 9.0 6.3
Killip. %
Class I 69.5 79.9 <0.0001
Class II 22.0 14.2
Class III 2.2 2.11
Class IV 6.3 3.8
Wall motion index. %
>1.6 21.1 34.1 <0.0001
1.3-1.6 20.9 23.9
0.8-1.2 40.1 31.1
<0.8 8.2 4.7
SD, standard deviation; NYHA, New York Heart Association;
P-values calculated with the use of chi2-test for discrete variables and t-test for continuous variables.
*History of heart failure and in-hospital heart failureKümler et al. Cardiovascular Diabetology 2010, 9:22
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plausible result from a biological point of view as diabetes
is a progressive and chronic disease.
Previous studies has documented that diabetes is a well
described predictor for an adverse outcome following
myocardial infarction [11]. Even patients with pre-dia-
betic conditions have an elevated risk of cardiovascular
disease [12], and it seems a progressive threshold
between blood glucose and cardiovascular risk exist, also
below the diabetic threshold [13]. Our results expand on
these findings by documenting continued prognostic
importance of diabetes with a follow-up period much
longer than any other study of this subject. In addition,
our results support a previous analysis of some of the
same patients suggesting that the magnitude of the prog-
nostic effect of diabetes may increase with time [4]. These
new results combined with the knowledge of many undi-
agnosed and thus untreated patients with diabetes under-
scores the necessity of an aggressive approach towards
diagnosing diabetes in MI patients.
It has been suggested that the glucometabolic state at
the time of admission for MI confers long-term prognos-
tic information in patients with and without diabetes
[14], which would mean that elevated blood glucose level
at admission with MI is not only a negligible expression
of acute physiological stress. This hypothesis is supported
by the observation that both in patients with and without
diabetes, blood glucose concentration at the time of
admission is related to the risk of death in patients admit-
ted with MI [15]. These studies underscore the close rela-
tionship between abnormal glucose metabolism and
ischemic heart disease which could be explained by more
extensive atherosclerosis in diabetic patients, a theory
supported by some, but not all studies [16,17]. Another
theory hypothesizes that metabolic disturbance could
have an adverse effect in the process of myocardial infarc-
tion. This was tested in trials where MI patients with dia-
betes where treated intensively with insulin to better
glycemic status. One trial showed an improvement in
long-term mortality but no effect on short term mortality
[18]. Another trial failed to show any benefit of the inter-
vention, but epidemiological analysis confirmed that glu-
cose level was a strong predictor of long-term mortality,
suggesting that glucose control is important [19]. A
smaller study showed no difference in mortality between
intervention and control group [20]. In conclusion, no
definitive effect of intensive treatment has been docu-
mented.
Of great interest is whether long-term intensive diabe-
tes treatment after discharge can lower the risk of devel-
oping new cardiovascular events. Epidemiological studies
and meta-analyses have shown a clear relationship
between haemoglobin A1C and the frequency of cardio-
vascular disease [21,22], and large studies have suggested
beneficial effects of intensive glucose regulation on the
risk of cardiovascular events, but such an effect has not
been clearly defined [23,24]. Recently, 3 large randomized
clinical studies failed to document an effect of intensive
glucose regulation on cardiovascular events [25-27].
Despite the lack of evidence for the effect of intensive
glucose regulation on cardiovascular events, we believe
there are several reasons why a more aggressive approach
to diagnosing diabetes is warranted. First, earlier diagno-
ses would have great significance for risk stratification by
identifying patients at high risk. Second, initiation of ear-
lier and more widespread medical treatment would be
possible. Improved prognosis would result, since the
effect of intensive glucose regulation on micro vascular
complications are well documented [23,24], as is multiple
risk factor intervention [28]. Third, the lack of docu-
mented effect of intensive glucose regulation on cardio-
vascular events in randomized trials could have other
Figure 1 Unadjusted all-cause mortality stratified by diabetes.
Figure 2 Landmark analysis of the time dependent prognostic 
significance of diabetes adjusted for age and gender.K
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Table 2: Proportional hazards models of mortality as a function of time
0-2 years 2-4 years 4-6 years 6-8 years 8-10 years 10-12 years 12-14 years 14-16 years +16 years
Variables RR CI* RR CI* RR CI* RR CI* RR CI* RR CI* RR CI* RR CI* RR CI*
Model 1
Diabetes 1.76 1.56-1.98 2.36 1.93-2.89 1.98 1.54-2.55 1.88 1.41-2.50 1.66 1.19-2.32 1.43 0.96-2.15 1.92 1.26-2.91 1.84 1.15-2.93 1.50 0.66-3.40
Model 2
Male gender 1.03 0.94-1.13 1.36 1.15-1.60 1.02 0.85-1.22 1.23 1.01-1.49 1.19 0.97-1.46 1.60 1.26-2.03 1.05 0.82-1.34 1.04 0.80-1.35 1.05 0.71-1.55
Age** 1.86 1.77-1.95 2.02 1.86-2.20 1.90 1.72-2.08 2.08 1.90-2.30 2.08 1.88-2.30 2.12 1.90-2.39 2.14 1.88-2.43 1.99 1.72-2.28 2.12 1.71-2.62
Diabetes 1.57 1.39-1.77 2.21 1.81-2.71 1.87 1.46-2.41 1.86 1.39-2.48 1.67 1.20-2.33 1.49 0.99-2.24 1.97 1.30-3.00 2.00 1.26-3.19 1.69 0.74-3.85
Model 3***
Male gender 0.99 0.89-1.10 1.29 1.08-1.54 1.03 0.85-1.24 1.31 1.07-1.61 1.08 0.87-1.34 1.64 1.27-2.12 1.05 0.80-1.37 1.11 0.82-1.49 0.99 0.64-1.53
Age** 1.45 1.37-1.54 1.71 1.55-1.88 1.69 1.52-1.86 1.88 1.69-2.10 1.90 1.69-2.10 1.99 1.74-2.24 1.97 1.71-2.28 1.90 1.64-2.20 2.14 1.68-2.71
Diabetes 1.19 1.04-1.37 1.92 1.54-2.38 1.66 1.27-2.17 1.57 1.16-2.12 1.34 0.94-1.90 1.40 0.91-2.16 2.09 1.37-3.20 2.13 1.33-3.42 1.86 0.80-4.32
*95% confidence interval
**Risk ratio associated with an increase in age of 10 years.
***Other covariates in model 3: Body mass index, previous AMI, angina pectoris, creatinine, congestive heart failure, diabetes mellitus, wall motion index, systemic hypertension, thrombolytic 
therapy.Kümler et al. Cardiovascular Diabetology 2010, 9:22
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explanations. The effect of intensive glucose treatment
could be modest in comparison with the well docu-
mented effect of treating other risk factors and thus diffi-
cult to document unless in longer trials with higher event
rate. The randomized trials have compared usual care
diabetes regulation with intensive regulation, but it is still
possible that cardiovascular events could be prevented
when comparing poor regulation with good regulation.
The population included in randomized trials had greater
presence of atherosclerosis suggested by long diabetes
duration, multiple risk factors or known cardiovascular
disease. Subset analyses have shown benefit of intensive
diabetes regulation in patients with lesser presence of
atherosclerosis [29]. Current strategies for regulation of
diabetes could have opposing effects on risk of cardiovas-
cular disease.
Our study has some limitations that need to be
acknowledged. When patients were screened for entry
into the TRACE study, thrombolytic therapy was admin-
istered routinely to ST-elevation MI patients. The stan-
dard treatment today in Denmark is percutaneous
coronary intervention. Moreover, almost all MI patients
today receive clopidogrel, statins and beta-blockers.
Some receive spironolactone or eplerenone. New phar-
macological treatment combinations are today available
to patients with diabetes. The most recent guidelines
state that patients with diabetes and albuminuria or
hypertension should be treated with an ACE inhibitor or
an angiotensin receptor blocker, even when the left ven-
tricular systolic function is normal [30]. This was not the
case at the start of the TRACE study, probably resulting
in an under-treatment of patients with diabetes during
the TRACE study period and the start of the follow-up.
These changes in the management of patients with MI
and diabetes could significantly influence our results.
However, a multivariable analysis from 1975 to the end of
2003 reveal only slight improvement in post discharge
survival after MI [31], but this is probably explained by a
lack of multivariate adjustment for MI complications,
medical and interventional treatment, as the survivors
had more aggressive treatment and fewer complications.
An important point is that we do not have information
regarding the medical treatment of patients with and
without diabetes during the follow-up period and thus
can not analyse potential differences. Since a number of
patients without diabetes at the time of the infarction
have developed diabetes later, the observed difference
between patients with and without diabetes is smaller
than the actual difference.
Many data shows that the diagnosis and treatment of
diabetes in cardiovascular patients is not adequately
done. New guidelines recommend oral glucose tolerance
test in patients with myocardial infarction but this is not
formally implemented. Our study is important as it
Figure 3 All cause mortality hazard ratio as a function of follow-up time for Cox proportional hazards model 1 (diabetes) and 3 (all covari-
ates).Kümler et al. Cardiovascular Diabetology 2010, 9:22
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underlines the importance of pinpointing the effect of
diabetes as a long-term prognostic factor in MI patients.
To our knowledge, this is the first study to systematically
evaluate the time-dependent development of diabetes as
a long-term prognostic factor in consecutive MI patients
with a follow-up of up to 17 years. The population
described here was recruited from 27 Danish hospitals
with regional patient uptake and can be considered to be
representative of patients with MI admitted alive in a
western industrialized country. By documenting the con-
tinued prognostic importance of diabetes as a prognostic
factor in patients with ischemic heart disease, our results
supports an aggressive approach towards diagnosing dia-
betes.
Conclusions
Diabetes is a long-term negative prognostic factor in MI
patients that continues to influence prognosis for up to 17
years after MI. This underscores the importance of an
aggressive diagnostic approach towards diabetes. The
presence of diabetes identifies MI patients at high-risk,
whom are candidates for continued aggressive medical
therapy.
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